Thomas Callender

M.B.Ch.B., M.Sc.

University College London

Wellcome Trust Clinical PhD Training Fellow

NLST (Learn more about this study)

NLST-806

Jun 21, 2021

Development and validation of prognostic models of lung cancer

Lung cancer remains the foremost cause of death from cancer worldwide. Screening for lung cancer could lead to a ~20% reduction in lung-cancer–specific mortality. However, current eligibility criteria – age and cumulative smoking exposure – remain contested, and several studies have shown the potential benefits of risk-based eligibility for screening. The NLST and PLCO trials have both formed the basis of several lung cancer risk prediction models, and have been used as a benchmark for comparing the performance of such models. The purpose of this project is to develop and validate prognostic models of lung cancer that have been developed in the UK Biobank in conjunction with the NLST in order to determine eligibility for lung cancer screening. This may involve combining the UK Biobank and NLST datasets, and/or the generation of synthetic participants from the datasets in order to augment and improve the data available for lung cancer predictive models.